DDrare: Database of Drug Development for Rare Diseases

Rc18 240 mg (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
11	Myasthenia	1
53	Sjogren syndrome	1

11. Myasthenia [ 226 clinical trials, 172 drugs, (DrugBank: 45 drugs), 43 drug target genes, 118 drug target pathways]

Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 226 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04302103 (ClinicalTrials.gov)	April 2020	6/3/2020	A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis	A Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Systemic Myasthenia Gravis	Systemic Myasthenia Gravis	Biological: RC18 160mg;Biological: RC18 240 mg	RemeGen	NULL	Recruiting	18 Years	70 Years	All	20	Phase 2	China

53. Sjogren syndrome [ 234 clinical trials, 270 drugs, (DrugBank: 85 drugs), 49 drug target genes, 174 drug target pathways]

Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 234 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04078386 (ClinicalTrials.gov)	June 28, 2019	18/7/2019	A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome	A Phase II Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Primary Sjögren's Syndrome	Primary Sjögren's Syndrome	Biological: Placebo;Biological: RC18 240 mg;Biological: RC18 160 mg	RemeGen	NULL	Recruiting	18 Years	65 Years	All	30	Phase 2	China